PMID- 34602370
OWN - NLM
STAT- MEDLINE
DCOM- 20220317
LR  - 20231213
IS  - 1879-4076 (Electronic)
IS  - 1879-4068 (Linking)
VI  - 13
IP  - 2
DP  - 2022 Mar
TI  - Efficacy and safety of ramucirumab plus docetaxel in older patients with advanced 
      non-small cell lung cancer: A multicenter retrospective cohort study.
PG  - 207-213
LID - S1879-4068(21)00205-8 [pii]
LID - 10.1016/j.jgo.2021.09.004 [doi]
AB  - OBJECTIVE: Ramucirumab (RAM) plus Docetaxel (DOC) is one of the standard 
      treatments after first-line treatment failure in patients with advanced non-small 
      cell lung cancer (NSCLC). However, little is known about the efficacy and safety 
      of RAM plus DOC in older patients. We aimed to clarify these and elucidate the 
      prognostic factors. MATERIALS AND METHODS: In this multicenter retrospective 
      study, conducted at four medical facilities in Japan, we evaluated the efficacy 
      and safety data for two groups (<65 and >/= 65 years). Progression-free survival 
      (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method and 
      log-rank test. Multivariate analysis was performed to reveal the prognostic 
      factors for better PFS and OS. Patient characteristics and adverse events (AEs) 
      in both groups were compared using the Mann-Whitney's U and Fisher's exact tests 
      for categorical variables. RESULTS: A total of 237 patients were included, of 
      whom 43% (n = 103), and 57% (n = 134) were aged <65, and >/= 65 years. Median OS 
      was 12.2 (95% CI: 9.4-15.0), and 14.8 months (95% CI: 10.8-18.8), respectively, 
      and there were no significant differences between the groups (p = 0.534). 
      Multivariate analysis identified DOC dose reduction (none vs performed, HR: 2.66, 
      95% CI: 1.62-4.35, p < 0.001) as an independent prognostic factor for OS in older 
      patients, and a similar result was shown for the PFS. Grade >/= 3 all AEs were 
      identified in 42.7% and 56.7% of younger and older patients, respectively, and 
      there was a significant difference between the groups (p = 0.033); however, the 
      difference between the groups disappeared with primary DOC dose reduction 
      (p = 0.526). CONCLUSION: The efficacy of RAM plus DOC administration in older, 
      pretreated patients with advanced NSCLC was comparable to those of younger 
      patients, whereas RAM plus DOC should be cautiously administered to older 
      patients because of severe toxicity. Moreover, appropriate DOC dose reduction may 
      be recommended for increased survival benefit and safety in such patients.
CI  - Copyright (c) 2021 Elsevier Ltd. All rights reserved.
FAU - Matsumoto, Kinnosuke
AU  - Matsumoto K
AD  - Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest 
      Medical Center, 1180 Nagasone-cho, Kita-Ku, Sakai City, Osaka 591-8555, Japan. 
      Electronic address: m.kinnosuke@gmail.com.
FAU - Tamiya, Akihiro
AU  - Tamiya A
AD  - Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest 
      Medical Center, 1180 Nagasone-cho, Kita-Ku, Sakai City, Osaka 591-8555, Japan.
FAU - Inagaki, Yuji
AU  - Inagaki Y
AD  - Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest 
      Medical Center, 1180 Nagasone-cho, Kita-Ku, Sakai City, Osaka 591-8555, Japan.
FAU - Taniguchi, Yoshihiko
AU  - Taniguchi Y
AD  - Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest 
      Medical Center, 1180 Nagasone-cho, Kita-Ku, Sakai City, Osaka 591-8555, Japan.
FAU - Matsuda, Yoshinobu
AU  - Matsuda Y
AD  - Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest 
      Medical Center, 1180 Nagasone-cho, Kita-Ku, Sakai City, Osaka 591-8555, Japan.
FAU - Kawachi, Hayato
AU  - Kawachi H
AD  - Department of Respiratory Medicine, Osaka International Cancer Institute, 3-1-69 
      Otemae, Chuo-Ku, Osaka City, Osaka 541-8567, Japan.
FAU - Tamiya, Motohiro
AU  - Tamiya M
AD  - Department of Respiratory Medicine, Osaka International Cancer Institute, 3-1-69 
      Otemae, Chuo-Ku, Osaka City, Osaka 541-8567, Japan.
FAU - Tanizaki, Satoshi
AU  - Tanizaki S
AD  - Department of Respiratory Medicine, Osaka General Medical Center, 3-1-56 Mandai 
      Higashi, Sumiyoshi-Ku, Osaka City, Osaka 558-8558, Japan.
FAU - Uchida, Junji
AU  - Uchida J
AD  - Department of Respiratory Medicine, Osaka General Medical Center, 3-1-56 Mandai 
      Higashi, Sumiyoshi-Ku, Osaka City, Osaka 558-8558, Japan.
FAU - Ueno, Kiyonobu
AU  - Ueno K
AD  - Department of Respiratory Medicine, Osaka General Medical Center, 3-1-56 Mandai 
      Higashi, Sumiyoshi-Ku, Osaka City, Osaka 558-8558, Japan.
FAU - Yanase, Takafumi
AU  - Yanase T
AD  - Department of Respiratory Medicine, Osaka Prefectural Medical Center for 
      Respiratory and Allergic Disease, 3-7-1 Habikino, Habikino City, Osaka 583-8588, 
      Japan.
FAU - Suzuki, Hidekazu
AU  - Suzuki H
AD  - Department of Respiratory Medicine, Osaka Prefectural Medical Center for 
      Respiratory and Allergic Disease, 3-7-1 Habikino, Habikino City, Osaka 583-8588, 
      Japan.
FAU - Atagi, Shinji
AU  - Atagi S
AD  - Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical 
      Center, 1180 Nagasone-cho, Kita-Ku, Sakai City, Osaka 591-8555, Japan.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20211001
PL  - Netherlands
TA  - J Geriatr Oncol
JT  - Journal of geriatric oncology
JID - 101534770
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 15H5577CQD (Docetaxel)
SB  - IM
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - Docetaxel/therapeutic use
MH  - Humans
MH  - *Lung Neoplasms/drug therapy
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Ramucirumab
OTO - NOTNLM
OT  - Docetaxel
OT  - Dose reduction
OT  - Non-small cell lung cancer
OT  - Older patient
OT  - Prognostic factor
OT  - Ramucirumab
COIS- Declaration of Competing Interest A. T. reported grants and personal fees from 
      AstraZeneca, Ono Pharmaceutical, and Bristol-Myers Squibb, and personal fees from 
      Eli Lilly Japan, Chugai Pharmaceutical, Boehringer Ingelheim, MSD, Pfizer, Taiho 
      Pharmaceutical, and Kissei Pharmaceutical. S. A. reported grants and personal 
      fees from AstraZeneca, Ono Pharmaceutical, Bristol-Myers Squibb, Eli Lilly Japan, 
      Boehringer Ingelheim, MSD, Pfizer, Taiho Pharmaceutical, Chugai Pharmaceutical, 
      and Merck Pharmaceutical; grants from F. Hoffmann-La Roche, and personal fees 
      from Kyowa Hakko Kirin and Hisamitsu Pharmaceutical. M. T. reported grants and 
      personal fees from Boehringer Ingelheim, Ono Pharmaceutical, and Bristol-Myers 
      Squibb, and personal fees from AstraZeneca, Eli Lilly Japan, Chugai 
      Pharmaceutical, MSD, Taiho Pharmaceutical, and Asahi Kasei Pharmaceutical. H. S. 
      reported personal fees from AstraZeneca, Chugai Pharmaceutical, and MSD. The 
      remaining authors declare that they have no conflict of interest.
EDAT- 2021/10/05 06:00
MHDA- 2022/03/18 06:00
CRDT- 2021/10/04 05:40
PHST- 2021/06/09 00:00 [received]
PHST- 2021/08/09 00:00 [revised]
PHST- 2021/09/03 00:00 [accepted]
PHST- 2021/10/05 06:00 [pubmed]
PHST- 2022/03/18 06:00 [medline]
PHST- 2021/10/04 05:40 [entrez]
AID - S1879-4068(21)00205-8 [pii]
AID - 10.1016/j.jgo.2021.09.004 [doi]
PST - ppublish
SO  - J Geriatr Oncol. 2022 Mar;13(2):207-213. doi: 10.1016/j.jgo.2021.09.004. Epub 
      2021 Oct 1.